Last year, Biogen Inc generated 2.15B USD for its biggest-performing segment, Spinal Muscular Atrophy-SPINRAZA. The United States made the largest contribution, accounting for 3.73B USD last year. For the latest quarter, Biogen Inc reported the revenue of 601.70M USD for the period ending 2026-06-30, which came from the top-performing segment, Spinal Muscular Atrophy-SPINRAZA. United States contributed the highest revenue, at 3.91B USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Spinal Muscular Atrophy-SPINRAZA

MS product revenues-TYSABRI

MS product revenues-Fumarate

MS product revenues-Interferon

Biosimilar product revenues-BENEPALI

Other-FUMADERM

Biosimilar product revenues-IMRALDI

Alzheimer's collaboration revenue

Biosimilar product revenues-FLIXABI

Biosimilars product Revenues -BYOOVIZ

MS product revenues-FAMPYRA

Alzheimer's disease:ADUHELM

Product revenues, net

Revenues from anti-CD20 therapeutic programs

Other revenues

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

Spinal Muscular Atrophy-SPINRAZA

2.15B(29.52%)

1.99B(27.33%)

1.80B(24.88%)

1.79B(22.45%)

1.91B(21.53%)

2.05B(19.19%)

--(--)

MS product revenues-TYSABRI

1.67B(22.82%)

1.72B(23.58%)

1.88B(25.90%)

2.03B(25.43%)

2.06B(23.32%)

1.95B(18.20%)

--(--)

MS product revenues-Fumarate

1.43B(19.55%)

1.60B(21.93%)

1.59B(21.92%)

2.00B(25.00%)

2.36B(26.70%)

3.91B(36.53%)

--(--)

MS product revenues-Interferon

945.60M(12.96%)

968.00M(13.31%)

1.11B(15.26%)

1.31B(16.34%)

1.57B(17.70%)

1.88B(17.56%)

--(--)

Biosimilar product revenues-BENEPALI

453.20M(6.21%)

479.10M(6.59%)

438.80M(6.06%)

441.00M(5.52%)

498.30M(5.63%)

481.60M(4.50%)

--(--)

Other-FUMADERM

197.20M(2.70%)

82.50M(1.13%)

7.80M(0.11%)

8.20M(0.10%)

11.00M(0.12%)

12.20M(0.11%)

--(--)

Biosimilar product revenues-IMRALDI

190.20M(2.61%)

213.10M(2.93%)

222.10M(3.06%)

224.50M(2.81%)

233.40M(2.64%)

216.30M(2.02%)

--(--)

Alzheimer's collaboration revenue

177.70M(2.44%)

59.90M(0.82%)

--(--)

Biosimilar product revenues-FLIXABI

52.60M(0.72%)

63.20M(0.87%)

77.40M(1.07%)

81.30M(1.02%)

99.40M(1.12%)

97.90M(0.92%)

--(--)

Biosimilars product Revenues -BYOOVIZ

33.10M(0.45%)

37.70M(0.52%)

31.70M(0.44%)

4.30M(0.05%)

--(--)

MS product revenues-FAMPYRA

1.40M(0.02%)

71.70M(0.99%)

90.50M(1.25%)

96.60M(1.21%)

105.20M(1.19%)

103.10M(0.96%)

--(--)

Alzheimer's disease:ADUHELM

--(--)

4.00M(0.06%)

4.80M(0.06%)

3.00M(0.03%)

--(--)

Product revenues, net

--(--)

11.38B(79.15%)

Revenues from anti-CD20 therapeutic programs

--(--)

2.29B(15.93%)

Other revenues

--(--)

707.70M(4.92%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

United States

Rest of world

United states-Revenues from anti-CD20 therapeutic

Rest of World-Other revenues

Rest of World

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

United States

3.73B(37.67%)

3.30B(34.08%)

3.14B(31.94%)

3.47B(34.10%)

3.81B(34.65%)

5.90B(43.88%)

6.71B(46.67%)

Rest of world

3.57B(36.11%)

--(--)

United states-Revenues from anti-CD20 therapeutic

1.86B(18.81%)

1.75B(18.09%)

1.69B(17.18%)

1.70B(16.72%)

1.66B(15.10%)

1.98B(14.71%)

2.29B(15.94%)

Rest of World-Other revenues

732.90M(7.41%)

652.60M(6.74%)

899.30M(9.14%)

485.10M(4.77%)

476.30M(4.34%)

774.60M(5.76%)

707.70M(4.92%)

Rest of World

--(--)

3.98B(41.09%)

4.11B(41.74%)

4.52B(44.41%)

5.04B(45.91%)

4.79B(35.64%)

4.67B(32.47%)